Organigram Global Targets Profitable Growth With Canada Focus and German Expansion

Key Points

• Organigram is narrowing its Canadian focus by reducing brands and SKUs, exiting lower-margin wholesale segments and concentrating investment on SHRED, BOXHOT and Big Bag O’ Buds to improve profitability.
• The Sanity Group acquisition has significantly increased Organigram’s international exposure: approximately 35% of revenue is now international, with Germany positioned as the main near-term growth market and expansion planned across several European countries.
• Management is targeting stronger cash generation and efficiency, including positive free cash flow in fiscal Q4, fiscal 2026 revenue of about CAD 350 million and improved adjusted EBITDA and gross margins, supported by manufacturing upgrades and tighter spending.

Organigram Global NASDAQ: OGI outlined a strategy centered on protecting its Canadian market position while increasing profitability, expanding internationally through its Sanity Group acquisition, improving manufacturing efficiency and applying stricter capital-allocation discipline.

At its 2026 Investor Session, CEO James Yamanaka said the company’s objective is to turn its market positions and operating capabilities into “sustained profitable growth, consistent cash generation, and shareholder value.” He described Canada as the company’s foundation, Germany as its near-term international growth opportunity, and operational improvements as a key link between the two businesses.

Canadian portfolio to become more focused

Yamanaka said Organigram intends to remain Canada’s recreational cannabis market-share leader but will not pursue revenue in segments that do not support margins. The company has reduced its SKU count by approximately 10% over the past year and exited certain wholesale white-label segments, according to Yamanaka.

Investment will increasingly be concentrated behind the SHRED, BOXHOT and Big Bag O’ Buds brands, he said. During a subsequent fireside chat, Yamanaka said he could see the company having roughly half its current number of brands and SKUs in four to five years, though he emphasized that the transition would be gradual.

Nick Robertson, Director of New Product Development and Innovation, said SHRED is Organigram’s highest-revenue brand, generating more than CAD 200 million in annual retail sales. The company is also rolling out its FAST nano-emulsion technology in SHRED gummies, beverages, shots and sodas. Robertson said a clinical study on FAST supported claims of faster onset and higher plasma concentrations in the bloodstream.

Sanity acquisition shifts revenue mix toward international markets

Organigram said its acquisition of Germany-based Sanity Group has changed the company’s geographic profile. In fiscal 2025, approximately 10% of Organigram’s net revenue came from outside Canada. With Sanity added in the third quarter, roughly 35% of revenue was international, Yamanaka said.

Sanity generated €19 million in revenue in the fourth quarter of fiscal 2025 before the acquisition, rising to €25.5 million two quarters later, a 34% increase, according to Yamanaka. CFO Greg Guyatt said Sanity contributed nearly CAD 40 million in net revenue in Organigram’s first full quarter of consolidation and was accretive to gross margin and adjusted EBITDA.

Finn Hänsel, Sanity’s founder and now Organigram’s President, Rest of World and Chief Strategy Officer, said Germany is the company’s scale market today. Its avaay Medical brand serves the private-pay medical channel, while VIAMED provides access to the reimbursed market and a network of German pharmacies.

Hänsel said Organigram expects the German medical cannabis market to double by 2028 and that Sanity is operating at an annualized revenue run rate of more than €100 million. He also cited expansion efforts in Switzerland, the United Kingdom, Poland, the Czech Republic, Slovenia and Ukraine, with the latter four markets expected to generate revenue within 18 months.

In Switzerland, Sanity operates two dispensaries under the country’s federal pilot program and has served thousands of participants, Hänsel said. The company observed illicit sourcing among participants decline by roughly 50%.

Manufacturing initiatives target quality, costs and European supply

Organigram highlighted cultivation, automation and product-development initiatives across its Canadian facilities. Matt Carreau, Senior Vice President of Operations East, said the Moncton site increased yield by 30,000 kilograms through cultivation improvements and achieved average potency above 30% in the third quarter.

Carreau also said the facility reduced room turnaround time from two days to less than 24 hours, creating capacity for more than 3,300 kilograms annually with little capital investment. Moving 95 grow rooms to alternating day-night schedules lowered electricity costs by roughly CAD 85,000 per month while maintaining production performance, he said.

Organigram is awaiting EU GMP certification for its Moncton facility. Guyatt said direct certification would eliminate the need to send flower to a third party for GMP conversion, a process that currently costs about CAD 0.50 per gram and adds approximately four to six weeks of working-capital time. Hänsel said EU GMP flower remains constrained in Germany, where demand is growing rapidly.

At Organigram’s Aylmer facility, the company has capacity to produce up to 4 million pre-rolls and 1.5 million vapes per month, according to operations leaders. Senior Director of Engineering Anna Mavil said quality-control improvements reduced vape complaints by 28% and pre-roll complaints by 29% from the end of the second quarter to the end of the third quarter.

Financial priorities and outlook

Guyatt said Organigram’s financial priorities are sustained free cash flow, stronger margins and a more stable cost structure. The company expects to generate positive free cash flow in the fourth quarter and reiterated its fiscal 2026 outlook for approximately CAD 350 million in revenue, with adjusted EBITDA and adjusted gross margin above fiscal 2025 levels.

In the third quarter, Organigram recorded its highest quarterly net revenue and adjusted EBITDA, with adjusted EBITDA margin returning to approximately 13%, Guyatt said. He added that the company’s SG&A expense ratio fell to about 31%, its lowest level in at least two years. Excluding depreciation and amortization and adjusting for a CAD 3 million bad-debt recovery, the ratio was approximately 26%.

Looking ahead, Guyatt said management sees an opportunity to reduce total SG&A further while improving gross margins. For Canada alone, he said the company is targeting gross margins in the mid-40% range through SKU rationalization, higher-margin product prioritization and production efficiencies.

Management said future acquisitions or investments will be assessed based on whether they strengthen the Canadian business, accelerate international expansion, improve manufacturing advantages and generate attractive long-term returns.

About Organigram Global (NASDAQ:OGI)

Organigram Global Inc is a Canadian cannabis company that develops, produces, and sells cannabis products for adult-use and medical markets. The company's portfolio includes dried flower, pre-rolls, cannabis-infused beverages, edibles, vapes, concentrates, and other cannabis-derived products.

Organigram markets products under several brands, including Edison Cannabis Co, SHRED, Big Bag O' Buds, Monjour, Trailblazer, and Holy Mountain. Its products are distributed through Canada's regulated cannabis retail and medical channels, with the company also pursuing international opportunities in select legal cannabis markets.

Founded in 2013, the company has expanded its production and brand portfolio through internal development and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.